RxDoctor Payments Data

Patrick Spencer

Nurse Practitioner · New York, NYNPI 1013164110

Payments from drug & device makers

$5,446in general payments, 2019–2025

Across 128 payments — averaging $42.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Sanofi$778
  • Janssen Scientific Affairs, LLC$455
  • Takeda Pharmaceuticals U.S.A., Inc.$453
  • Bristol Myers Squibb$424
  • Karyopharm Therapeutics Inc.$404
  • plus $841 from 8 others

What the payments were for

  • Consulting fees$3406%
  • Food & beverage$4,54583%
  • Education$56110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,446 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$2,472
Medicare patients
20
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide46$765,173
PomalystPomalidomide26$554,381
Lenalidomide38$449,687
XpovioSelinexor11$281,369
Atovaquone11$3,876
ValacyclovirValacyclovir Hcl27$1,046
Acyclovir33$506
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim37$254
Dexamethasone35$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$424$765,17346 claims
Karyopharm Therapeutics Inc.Xpovio$404$281,36911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →